Real-world Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients (Brentuximab-5020)

First published 24/05/2023

Last updated 30/10/2025

EU PAS number:

EUPAS104804

Study

Finalised

Documents

Study protocol

Initial protocol

Brentuximab-5020-clinical-study-protocol-redact.pdf

English (1.95 MB - PDF) View document

Updated protocol

Brentuximab-5020-clinical-study-protocol amendment-redact.pdf

First published: 30/10/2025

English (2.14 MB - PDF) View document

Study results

Study report

Brentuximab-5020-clinical-study-report-redact.pdf

English (817.93 KB - PDF) View document

Other information

Secondary tabs